Cytomegalovirus immediate-early 1 peptide-major histocompatibility complex (CMV IE-1 pMHC)

Cytomegalovirus immediate-early 1 (IE-1) peptide-major histocompatibility complex (pMHC) is a primary immunological target for the cellular immune response against Human Cytomegalovirus (HCMV). The IE-1 protein, encoded by the UL123 gene, is expressed immediately upon viral entry and plays a crucial role in transactivating viral and host genes, making it an early marker of infection (PMID: 15976050). These complexes are formed when proteasome-derived IE-1 peptides are loaded onto MHC Class I molecules in the endoplasmic reticulum and subsequently presented on the cell surface. CD8+ T cells recognize these specific pMHC complexes via their T-cell receptors (TCRs), which is essential for controlling viral latency and reactivation (PMID: 25609814). In clinical development, CMV IE-1 pMHC complexes are targeted by adoptive cell therapies, including donor-derived CMV-specific T cells and TCR-engineered T cells, to treat or prevent CMV disease in immunocompromised patients, such as those undergoing hematopoietic stem cell transplantation (PMID: 30206139). Therapeutic strategies also include vaccines that aim to elicit robust IE-1-specific T-cell responses to provide long-term protection against CMV-related complications.

Other names

HCMV IE1 peptide-HLA complexIE1-MHC complexImmediate-early protein 1 peptide-MHCUL123 peptide-MHCCMV IE1-HLA-A*02:01 complex

Recognition by T-cell receptors (TCRs) on CD8+ cytotoxic T lymphocytes, leading to the targeted lysis of CMV-infected cells and the release of antiviral cytokines like IFN-gamma.